Citations 1
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
Shadman, Mazyar, ChananâKhan, Asher , Campbell, David , Xue, Mei, Massoudi, Marjan , Williams, Rhys, Yang, Keri, Tam, Constantine S., Tam, Constantine S. , Shadman, Mazyar , Shadman, Mazyar , Xue, Mei , Tam, Constantine S , Williams, Rhys
Future Oncology | January 31, 2026 | Volume: 22 | Issue: 3 | Pages: 339-348
